Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia-Reference-Cited by-同舟云学术

Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia

Published:2015-07-29 Issue:5 Volume:80 Page:1001-1009
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Assouline Sarit¹,Buccheri Valeria²,Delmer Alain³,Gaidano Gianluca⁴,McIntyre Christine⁵,Brewster Michael⁵,Catalani Olivier⁶,Hourcade-Potelleret Florence⁶,Sayyed Pakeeza⁶,Badoux Xavier⁷

Affiliation:

1. Jewish General Hospital; Montreal Canada

2. Hematology Division; Hospital das Clinicas da Faculdade de Medicina da Universidade de Săo Paulo; Săo Paulo Brazil

3. Hematologie Clinique; Hôpital Robert Debré; Reims France

4. Division of Hematology, Department of Translational Medicine; Amedeo Avogadro University of Eastern Piedmont; Novara Italy

5. Roche Products Ltd; Welwyn Garden City UK

6. F. Hoffmann-La Roche Ltd; Basel Switzerland

7. Department of Haematology; St. George Hospital; Kogarah Australia

Funder

F. Hoffman-La Roche

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.12662/fullpdf

Reference20 articles.

1. International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial;Hallek;Lancet,2010

2. PrefHer Study Group. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study;Pivot;Lancet Oncol,2013

3. German Chronic Lymphocytic Leukemia Study Group. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group;Stilgenbauer;J Clin Oncol,2009

4. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration;Frost;Expert Opin Drug Deliv,2007

5. A recombinant human enzyme for enhanced interstitial transport of therapeutics;Bookbinder;J Control Release,2006

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel dosing approach for rituximab in glomerular diseases based on a population pharmacokinetic analysis;Biomedicine & Pharmacotherapy;2024-06

2. Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors;Clinical Cancer Research;2024-02-06

3. Time‐dependent clearance can confound exposure–response analysis of therapeutic antibodies: A comprehensive review of the current literature;Clinical and Translational Science;2023-11-14

4. Advancing Subcutaneous Dosing Regimens for Biotherapeutics: Clinical Strategies for Expedited Market Access;BioDrugs;2023-10-13

5. Evaluation of the economic benefits, administration times, and patient preferences associated with the use of biotechnological drugs administered subcutaneously and intravenously in patients with cancer: a systematic review;Expert Review of Pharmacoeconomics & Outcomes Research;2023-09-04